870 - Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)

Friday, October 21, 2022

11:00 AM – 11:15 AM US ET

Location: 147 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Presenting Author(s)

Johan A. Maertens, MD PhD

Professor
KU Leuven
Leuven, Brussels Hoofdstedelijk Gewest, Belgium

Disclosure: Disclosure(s): F2G Ltd: Advisor/Consultant (); Gilead Sciences Ltd: Advisor/Consultant (); Mundipharma: Advisor/Consultant (); Pfizer Inc: Advisor/Consultant ()

Co-Author(s)

PV

Paul E. Verweij, PhD

Prof
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands

Disclosure: Disclosure(s): Gilead: Grant/Research Support ()
EL

Evan F. Lanuza, n/a

Director
Kern Medical
Paso Robles, California, United States

Disclosure: Disclosure(s): No financial relationships to disclose
EH

Emma L. Harvey, MBBS

Global Head of Medical Affairs
F2G Ltd
Egham, England, United Kingdom

Disclosure: Disclosure(s): F2G Ltd: Stocks/Bonds ()
AD

Aaron Dane, MSc

Director
Danestat Consulting Limited
Macclesfield, England, United Kingdom

Disclosure: Disclosure(s): Amplyx: Advisor/Consultant (); AN2 therapeutics: Advisor/Consultant (); Artizan: Advisor/Consultant (); Cidara: Advisor/Consultant (); ContraFect: Advisor/Consultant (); Correvio: Advisor/Consultant (); Davolterra: Advisor/Consultant (); Destiny Pharma: Advisor/Consultant (); Entasis: Advisor/Consultant (); F2G Limited: Advisor/Consultant (); GSK: Advisor/Consultant (); Humanigen: Advisor/Consultant (); Kymab: Advisor/Consultant (); Modis: Advisor/Consultant (); Orca: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Phico: Advisor/Consultant (); Pled Pharma: Advisor/Consultant (); Rare Thyroid: Advisor/Consultant (); Roche: Advisor/Consultant (); Scynexis: Advisor/Consultant (); Sinovent: Advisor/Consultant (); Spero Therapeutics: Advisor/Consultant (); Transcrip: Advisor/Consultant (); Venatorx: Advisor/Consultant ()
DZ

Daniela Zinzi, Infectious Diseases Specialist

F2G
Manchester, England, United Kingdom

Disclosure: Disclosure(s): F2G: F2G employee (), Stocks/Bonds ()
John H. Rex, MD

Chief Medical Officer
F2G, Limited
WELLESLEY HILLS, MA, United States

Disclosure: Disclosure(s): Advent Life Sciences: Operating Partner (), Ownership Interest (); AMR Action Fund: Advisor/Consultant (); AstraZeneca: Stocks/Bonds (); Basilea Pharmaceutica: Advisor/Consultant (); Bugworks Research, Inc.: Advisor/Consultant (); F2G, Limited: Employee (), Stocks/Bonds (); Forge Therapeutics: Advisor/Consultant (); GlaxoSmithKline: Advisor/Consultant (); Pfizer Pharmaceuticals: Honoraria (); Sumitovant: Advisor/Consultant ()
SC

Sharon C. Chen, PhD MBBS

Professor
Westmead Hospital
Sydney, New South Wales, Australia

Disclosure: Disclosure(s): F2G PTy Ltd: Grant/Research Support (); MSD Australia: Grant/Research Support ()

Disclosure(s):

Johan A. Maertens, MD PhD: F2G Ltd: Advisor/Consultant (); Gilead Sciences Ltd: Advisor/Consultant (); Mundipharma: Advisor/Consultant (); Pfizer Inc: Advisor/Consultant ()

Paul E. Verweij, PhD: Gilead: Grant/Research Support ()

Evan F. Lanuza, n/a: No financial relationships to disclose

Emma L. Harvey, MBBS: F2G Ltd: Stocks/Bonds ()

Aaron Dane, MSc: Amplyx: Advisor/Consultant (); AN2 therapeutics: Advisor/Consultant (); Artizan: Advisor/Consultant (); Cidara: Advisor/Consultant (); ContraFect: Advisor/Consultant (); Correvio: Advisor/Consultant (); Davolterra: Advisor/Consultant (); Destiny Pharma: Advisor/Consultant (); Entasis: Advisor/Consultant (); F2G Limited: Advisor/Consultant (); GSK: Advisor/Consultant (); Humanigen: Advisor/Consultant (); Kymab: Advisor/Consultant (); Modis: Advisor/Consultant (); Orca: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Phico: Advisor/Consultant (); Pled Pharma: Advisor/Consultant (); Rare Thyroid: Advisor/Consultant (); Roche: Advisor/Consultant (); Scynexis: Advisor/Consultant (); Sinovent: Advisor/Consultant (); Spero Therapeutics: Advisor/Consultant (); Transcrip: Advisor/Consultant (); Venatorx: Advisor/Consultant ()

Daniela Zinzi, Infectious Diseases Specialist: F2G: F2G employee (), Stocks/Bonds ()

John H. Rex, MD: Advent Life Sciences: Operating Partner (), Ownership Interest (); AMR Action Fund: Advisor/Consultant (); AstraZeneca: Stocks/Bonds (); Basilea Pharmaceutica: Advisor/Consultant (); Bugworks Research, Inc.: Advisor/Consultant (); F2G, Limited: Employee (), Stocks/Bonds (); Forge Therapeutics: Advisor/Consultant (); GlaxoSmithKline: Advisor/Consultant (); Pfizer Pharmaceuticals: Honoraria (); Sumitovant: Advisor/Consultant ()

Sharon C. Chen, PhD MBBS: F2G PTy Ltd: Grant/Research Support (); MSD Australia: Grant/Research Support ()